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Gastroesophageal reﬂux disease (GORD) is increasing in prevalence and is highly associ-
atedwith several lung diseases such as asthma and COPD. Current diagnostic methods are
imperfect, being insensitive, non-speciﬁc, expensive, or invasive. An accurate diagnosis of
GORD can aid effective treatment and have signiﬁcant clinical impact. Novel methods such
as exhaled breath condensate analysis and electronic nose technology have the potential
to improve the accuracy of diagnosing GORD.
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INTRODUCTION
Gastroesophageal reﬂux is the passage of gastric contents through
the gastric cardia into the esophagus. The Montreal consensus of
2006 deﬁned gastroesophageal reﬂux disease (GORD) as a pathol-
ogy which “develops when the reﬂux of stomach contents causes
troublesome symptoms or complications” (Vakil et al., 2006). The
ambiguity of this deﬁnition hints at the imprecise nature of GORD
diagnosis. Clinically, the diagnosis of GORD is most commonly
achieved using symptom evaluation with a validated question-
naire, empiric proton pump inhibitor (PPI) therapy, or esophageal
pH monitoring. Research is ongoing into these and other meth-
ods of diagnosis, as well as risk factors and associations, in order
to develop more effective clinical management.
Risk factors for developing GORD include hiatus hernia
(Beaumont et al., 2010), obesity (Sise and Friedenberg, 2008;
Fisichella and Patti, 2009), pregnancy (Baron and Richter, 1992),
and smoking (Isolauri and Laippala, 1995). GORD is also asso-
ciated with many factors, including the lung diseases COPD and
asthma (Amarasiri et al., 2010). COPD is characterized by a min-
imally reversible reduction in expiratory airﬂow whilst asthma
is a common disease that is characterized by airﬂow obstruction
that changes both with treatment and spontaneously. Whether
the association of COPD and asthma with GORD represents
cause or effect has yet to be established (Maher and Darwish,
2010). It has been shown, however, that treatment of GORD can
improve symptoms if not lung function in asthmatics (Gibson
et al., 2000). In COPD patients, the presence of GORD is associ-
ated with increased exacerbations of COPD (Rascon-Aguilar et al.,
2006; Terada et al., 2008) and limited evidence suggests treatment
with PPIs can improve symptoms if not lung function (Eryuksel
et al., 2009).
The estimates of the prevalence of GORD in COPD patients
range widely in the literature. The limited number of studies
which used the gold standard of 24 h esophageal pH monitoring
estimated the prevalence between 19 (Dent et al., 2005) and
57% (Kempainen et al., 2007). The disparities in prevalence
may be attributable to the demographics of the study popula-
tion (e.g., one study which had an almost entirely male cohort;
Casanova et al., 2004), different monitoring devices, use of prox-
imal or distal monitoring, and variability in the pH criteria
(Delaney, 2004).
The prevalence of GORD in asthma has varied between stud-
ies using pH monitoring from 36 to 55% (Kiljander and Laitinen,
2004;Leggett et al.,2005). Several studies have shownan increase in
the prevalence of GORD in both difﬁcult-to-control asthma and
more severe asthma (Leggett et al., 2005). Disparities in preva-
lence studies again may be attributable to study demographics,
monitoring techniques, and pH criteria.
Gastroesophageal reﬂux disease is a concern in COPD, asthma,
and many other lung diseases as it may cause bronchospasm
and related wheezing or coughing (Canning and Mazzone, 2003;
Rascon-Aguilar et al., 2006). A recent Cochrane review examined
the conﬂicting evidence on the beneﬁt of GORD treatment [pro-
ton pump inhibitors (PPIs), histamine antagonists, and surgical
treatment] for managing asthmatic lung disease. PPI treatment,
histamine antagonist therapy or surgical therapy may improve
asthma-related quality of life and decrease symptoms in some
groups of patients; however such treatment may not improve lung
function (Gibson et al., 2000). Furthermore, it is difﬁcult to pre-
dict which types of patients will beneﬁt from this. Being able to
diagnose GORD is an important aid to management of a patient’s
lung disease even if it only improves symptoms rather than lung
function.
Current methods for diagnosis of GORD have limited accuracy
or are invasive. The most commonly used methods of diagnosis
are a symptom questionnaire or empiric PPI therapy. These meth-
ods however have limited sensitivity and speciﬁcity. Esophageal
pH monitoring (24 h) with multichannel intraluminal impedance
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(MII) monitoring is the gold standard, but is invasive and time
consuming (Aanen et al., 2008).
CURRENT METHODS OF GORD DIAGNOSIS
SYMPTOM QUESTIONNAIRES
Gastroesophageal reﬂux disease is often suspected because of
symptoms reported by the patient and these symptoms can
be formally assessed using validated questionnaires. Question-
naires are quick, non-invasive, and inexpensive but cannot detect
asymptomatic GORD.
Several questionnaires have been developed and validated.
These include the Reﬂux Disease Questionnaire (RDQ; Dent et al.,
2010), the frequency scale for symptoms of gastroesophageal
(FSSG) Reﬂux Disease (Kusano et al., 2004), and the Re-Quest
Questionnaire (Rubin et al., 2008). Symptom evaluation is also
useful for assessing treatment efﬁcacy. A study of night-time
GORD symptoms in otherwise healthy participants indicated that
night-time symptoms were both common, occurring in 45% of
patients, and indicated a greater severity of disease burden than
patients with primarily or exclusively day time symptoms (Dean.
et al., 2010).
LARYNGOPHARYNGEAL EXAMINATION
Following a thorough clinical history and symptom assessment,
the laryngopharynx may be examined for signs of reﬂux. Exami-
nation of the laryngopharynx provides valuable diagnostic infor-
mation to symptoms and can give an indication of impact on
the patient. Laryngopharyngeal reﬂux differs from GORD as
it may also present with throat symptoms such as dysphonia,
pseudodysphagia, and globus (Pearson et al., 2011).
Examination of the laryngopharynx is performed using a ﬂexi-
ble or rigid laryngoscope. Typical ﬁndings from a laryngopharyn-
goscopy of a patient with laryngopharyngeal reﬂux include: ery-
thema,posterior commissure hypertrophy,granulomas,vocal cord
dysfunction, pseudosulcus, edema, ventricular obliteration, ery-
thematous mucosa in the nasopharynx, and red mucosa in the
lingual tonsils. Findings on laryngopharyngoscopy consistent with
reﬂux disease are often followed by an empiric trial of PPIs
(Pearson et al., 2011).
EMPIRIC PROTON PUMP INHIBITOR TRIAL
A common step after presentation with GORD symptoms is to
trial an empiric course of PPIs before performing further investi-
gations.APPI therapeutic trial has been shown tobe fairly sensitive
(68–92%) with a wide range of speciﬁcity (36–100%) in diagnos-
ing GORD-related non-cardiac chest pain (Fass et al., 1998; Bate
et al., 1999; Pandak et al., 2002; Cho et al., 2010). In addition,
empirical treatment with PPIs ensures early therapeutic interven-
tion. One recent study has however cast some doubt on whether
symptom response to 40mg of esomeprazole over a 2-week period
is sensitive or speciﬁc for the diagnosis of GORD when compared
to esophageal pH monitoring (Dent et al., 2010). Empirical PPI
therapy however remains the main treatment for GORD.
ESOPHAGEAL PH MONITORING
Whilst symptomatic evaluation and empiric PPI trials are the
most commonly used methods of diagnosis, esophageal pH
monitoring is highly sensitive, and speciﬁc. Esophageal pH mon-
itoring involves leaving a pH probe 5 cm superior to the lower
esophageal sphincter for a 24-h period. During the 24-h, the
patient records their meals, symptoms, and sleep. The esophageal
acid exposure is then determined by the percentage of the 24-h
period that the pH is< 4.0. Symptoms do not always correlate
with pH< 4, however, as symptoms can result from non-acidic as
well as acidic reﬂux.
Esophageal pHmonitoring can be supplemented byMII testing
to detect non-acidic reﬂux. MII testing identiﬁes causes of reﬂux
symptoms which occur without lowering the pH below 4. Other
causes of reﬂux symptoms include minor acid (pH 4–7), non-
acid, and gas reﬂux. Esophageal pH monitoring with MII testing
is sensitive and speciﬁc however it is invasive, expensive, and time
consuming.
In the detection of acid reﬂux, 24 h pHmonitoringwithoutMII
yields a sensitivity of 68%, and a speciﬁcity of 67% (Amine et al.,
2007). For the detection of weakly acidic reﬂux compared with
MII, pH alone had a sensitivity of only 28%. The use of 24 h pH
monitoring alone for the detection of acid reﬂux is very sensitive
but lacks speciﬁcity compared with MII–pH monitoring (Amine
et al., 2007).
ENDOSCOPY
Endoscopy is also invasive and has high sensitivity for diagnosing
mucosal injury but is not typically performed as an initial investi-
gation for GORD symptoms. Endoscopy is performed in a minor-
ity of patients to obtain further information relating to GORD and
is useful for detection of esophagitis, erosions, strictures, ulcers,
neoplasia, and Barrett’s esophagus (Reid et al., 1988).
Whilst invasive tests such as endoscopy and esophageal pH
monitoring are effective as diagnostic tools, there is no current
test with high sensitivity and speciﬁcity which is also inexpensive
and non-invasive. A potential method for screening and diagnos-
ing GORD and micro-aspiration in patients may be the proﬁling
of patients’ breath.
NOVEL METHODS OF DIAGNOSING GORD
Breath proﬁling is used informally by doctors in a range of clinical
scenarios, from detecting the “fruity breath”of diabetic patients in
ketoacidotic states to smelling alcohol on the breath. The breath
can be formally proﬁled using a range of tools including electronic
nose analysis, fractional nitric oxide measurements, and exhaled
breath condensate (EBC) collection. With regard to reﬂux, one
method may be the detection of either pepsin or bile acids in the
exhaled breath secondary to aspiration of gastric contents. Nitric
oxide levels and volatile organic compounds are also of signiﬁcant
interest and are examined using fractional exhaled nitric oxide
measurements and electronic nose technology.
PEPSIN – A DIAGNOSTIC MARKER OF REFLUX
Pepsin is a gastric enzyme that degrades food proteins into pep-
tides. In patients with GORD, elevated levels of pepsin have
recently been described in the respiratory epithelial lining ﬂuid
using EBC (Krishnan et al., 2007), using bronchoalveolar lavage
(BAL; Farrell et al., 2006), and via the sampling of middle ear
effusions of children with pharyngeal reﬂux (Abd El-Fattah et al.,
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Table 1 | Pepsin concentration in EBC and BAL.
Study population Sampling
method
Pepsin concentration Analytical techniques
Adult lung transplant (LTx) patients
experiencing GORD (Krishnan et al.,
2007)
EBC Higher in the LTx with GORD (mean
concentration 4.31 ng/mL) than controls
(mean concentration 0.08 ng/ml)
In-house ELISA assay using antiporcine pepsin
antibodies (Krishnan et al., 2002)
Mean concentration compared using a
Mann–Whitney U test (Krishnan et al., 2002)
Cystic ﬁbrosis patients (McNally
et al., 2011)
BAL Higher in the CF group (mean concentration
24.4 ng/ml) than in controls (4.3 ng/ml)
Pepsin was measured by an in-house ELISA assay
with antiporcine pepsin antibodies (Farrell et al., 2006)
Groups and subgroups were analyzed using
two-tailed independent sample students’ t tests
when normally distributed or by the non-parametric
Mann–Whitney U test, as appropriate
Children with GORD (Farrell et al.,
2006)
BAL Pepsin concentration ranged from 0 to
100 ng/ml
Pepsin was measured using an in-house ELISA assay
with antiporcine pepsin antibodies (Farrell et al., 2006)
Correlations between factors were tested using the
two-tailed Spearman correlation coefﬁcient
Lung allograft patients (Ward et al.,
2005)
BAL Median concentration of 109 ng/ml (range
35–1375) in lung allograft patients
A locally developed ELISAwas performed tomeasure
pepsin. The assay was based on a monospeciﬁc
antibody to porcine pepsin with a lower limit of
detection of <1ng/ml
Two-tailed Mann–Whitney U tests were performed to
compare the median pepsin concentration between
groups
Children with different chronic lung
diseases (Starosta et al., 2007)
BAL Mean pepsin concentration varied from 0 to
1517 ng/ml across a spectrum of GORD
A modiﬁcation of the proteolytic enzyme assay
method was used to measure pepsin
The non-parametric Mann–Whitney U test was used
to compare between groups
2007; see Table 1). The advantage of analyzing pepsin is that it is
not normally found in the lung and therefore should be speciﬁc
for reﬂux.
BRONCHOALVEOLAR LAVAGE
Bronchoalveolar lavage is an invasive but direct method of sam-
pling the lung epithelial lining ﬂuid. BAL involves inserting a
bronchoscope through the mouth or nose into the lungs. The
bronchoscopist can instill ﬂuid into a small part of the lung and
then collects the ﬂuid for examination.
Pepsin has been detected in the BAL of subjects in several
lung diseases. Some lung allograft patients (Ward et al., 2005)
have been shown to have pepsin present in BAL, as have children
with different chronic lung diseases including chronic bronchitis
without a determinable cause; allergic asthma; recurrent pneu-
monia; bronchiectasis; tracheomalacia; primary ciliary dyskinesia;
and bronchiolitis obliterans (Starosta et al., 2007).
EXHALED BREATH CONDENSATE
Exhaled breath condensate is the breath water vapor that has been
condensed, typically via cooling using a collection device (com-
monly to 4˚C or sub-zero temperatures). EBC reﬂects changes
in the respiratory ﬂuid that lines the airways and is an inexpen-
sive, non-invasive sampling tool. Pepsin has been demonstrated in
the EBC of patients who were clinically suspected to have reﬂux
associated cough (Strugala et al., 2009).
Exhaled breath condensate has been used to investigate the
relationship between reﬂux symptoms and lung disease in one
previous paper (Terada et al., 2008). EBC pH was studied in 82
patients with COPD and 42 controls and was found to be signif-
icantly lower in patients with GORD (Terada et al., 2008).GORD
symptomswere signiﬁcantly predictive of COPDexacerbation and
an inverse correlation was determined between EBC pH and the
FSSG score (Terada et al., 2008).
Exhaledbreath condensate pHdecreases in active inﬂammatory
lung conditions, including asthma and particularly during exac-
erbations (Brunetti et al., 2004) but not in COPD (Antus et al.,
2010). Aspiration of acidic stomach contents may however inﬂu-
ence the pH of EBC and its accuracy as a marker of disease. Pepsin
therefore has potential use as a marker of gastric aspiration if an
acidic EBC is detected (Hunt et al., 2000). Pepsin levels have also
been shown to correlate with percentages of neutrophils, levels of
protein carbonyls, and levels of IL-8 in BAL (Starosta et al., 2007).
ELECTRONIC NOSE TECHNOLOGY
An electronic nose is a device that partially imitates the mam-
malian olfactory system which can formally analyze breath
proﬁles. Several different types are now commercially available.
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Usually, it utilizes sensor array and pattern recognition algorithms
to identify components in vapor. An array of sensors using coated
electrodes or polymer composites respond to the volatile compo-
nents, causing the coating to change or polymer to expand like a
sponge, changing the electrical resistance of the composites. The
change in resistance is measured and used to indicate the presence
of a pre-trained pattern. Another type of electronic nose makes
uses of an array of quartz microbalance gas sensors coated by mol-
ecular ﬁlms of metalloporphyrins. The array of sensors quantiﬁes
the amount of molecules that are absorbed by the molecular ﬁlms
by the changes in resonant frequency. These changes in frequency
are then analyzed by pattern recognition algorithms (Montuschi
et al., 2010).
The precise chemicals detected are not identiﬁed, only a pat-
tern or “smell print” is established for each condition. There are
currently several electronic noses in use, e.g., the Cyranose 320
(Smith’s Detection, San Diego, USA), the Bloodhound (Scensive
Technologies, Normanton, UK), and the Grafﬁt-e-Nos (E-Nose
Pty Ltd, Sydney, Australia).
Whilst initially developed for use in situations such as indoor
atmosphere maintenance, military gas analysis, and food prepara-
tion, electronic nose technology has found applications in med-
icine. The electronic nose has the potential to sample volatile
compounds in breath,wounds, and bodily ﬂuid. Due to the diverse
range of samples which electronic nose technology can assess,
research is ongoing in diverse disorders such as urinary tract infec-
tions (Pavlou et al., 2002), lung cancer (Machado et al., 2005; Tran
et al., 2010), cerebrospinal ﬂuid leak (Thaler et al., 2000), and
diabetes mellitus (Ping et al., 1997) among others.
Standardization of breath sampling is critical for the continued
use of electronic nose technology. Use of a streamlined, validated,
protocol is crucial for comparison between studies. One develop-
ment in exhaled breath sampling was the use of a two Tedlar bag
valve system which allows sampling of the lower respiratory tract
only (D’Amico et al., 2010). A signiﬁcant problem with breath
sampling is potential contamination by food, drinks, and other
items in the upper airways. Sampling of only the lower respira-
tory tract helps to eliminate some of the variability associated
with the upper airways and in general, alveolar air is contained
in the last portion of an expiratory breath. Montuschi et al.
(2010) also demonstrated sampling of alveolar air by an electronic
nose to be accurate in detecting atopic asthma, particularly in
conjunction with exhaled nitric oxide testing (Montuschi et al.,
2010).
Current diagnostic potential in GORD
Whilst no study has examined whether the electronic nose can
separate reﬂux patients from healthy controls, several studies have
assessed the ability of the electronic nose to discriminate the
breath proﬁles of patients with asthma, COPD, lung cancer, and
other lung diseases.With pre-existing information on lung disease
breath proﬁles, it is possible not only to study GORD in isolation
but also in conjunction with lung disease.
Breath proﬁling has been performed on several lung diseases.
At a basic level, changes in breath proﬁles resulting from active
smoking allow for discrimination between smokers and non-
smokers with a sensitivity of 95% (Chen et al., 2009). Smokers
overlap with COPD patients, however patients with COPD had
a negligible change in breath compared to asthma, ex-smokers,
and non-smokers (Fens et al., 2009). One study in the bron-
choscopy unit of a large hospital showed the electronic nose was
able to discriminate between lung cancer and healthy controls.
This study also showed a modiﬁcation of breath by other dis-
eases including pleurisy, bronchitis, and COPD (D’Amico et al.,
2010).
A key point that has emerged from the study of several lung
diseases is that the electronic nose is most effective when distin-
guishing between two distinct subgroups. When Fens et al. (2009)
analyzed asthma, COPD, smokers, and non-smokers all together
the sensitivity was only 56%, although this was statistically signif-
icant. Electronic noses may be best used distinguishing between
two clearly deﬁned groups.
GAS CHROMATOGRAPHY AND MASS SPECTROMETRY
Gas chromatography and mass spectrometry involves a combi-
nation of gas liquid chromatography and mass spectrometry to
identify various substances. It is particularly useful for identifying
traces of compounds that are detectable only at very low levels.
Gas chromatography mass spectrometry has been used in
analysis of breath in parallel with the electronic nose in asthma and
normal subjects (Hyspler et al., 2000; Dallinga et al., 2010). To date
no analysis of a patient’s breath with GORD has been performed
usingGCMS. The use of GCMS is limited in standard clinical prac-
tice due to its size, cost, and technical requirements. The electronic
nose however has the potential to allow real time measurement of
exhaled breath in clinical practice, but this requires appropriate
evaluation.
Novel, non-invasive but accurate methods of conﬁrming a
diagnosis of GORD could help the signiﬁcant numbers of
patients needlessly on PPI treatment and also those patients who
are asymptomatic but who would beneﬁt from such treatment
(Raman et al., 2010). Up to 10–30% of Western populations are
affected by GORD (Spechler, 1992; Frank et al., 2000; Holtmann,
2001), there is a higher prevalence amongst lung disease patients
and there is evidence suggesting that the prevalence of GORD is
increasing (Friedenberg et al., 2010). Now more than ever, further
research into standard and novel methods of diagnosis is needed.
CONCLUSION
Gastroesophageal reﬂux disease is a prevalent disorder in West-
ern countries and is increasing in prevalence. GORD can cause
signiﬁcant morbidity and have an impact on quality of life, partic-
ularly in association with lung disease. Whilst debate continues as
to whether lung disease exacerbates GORD or GORD exacerbates
lung disease, accurate diagnosis, and subsequent treatment of this
disease should be able to improve outcome. Diagnosis of GORD
is an evolving ﬁeld but research is hampered by blurred deﬁni-
tions of what constitutes GORD. Measurement of exhaled breath
and EBC in reﬂux patients may represent the intermediate step
between diagnostic accuracy and non-invasive sampling. Whilst
research has demonstrated potential in these methods, further
research needs to be undertaken in large populations, prefer-
ably comparing electronic nose, and EBC to other methods of
diagnosis.
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